Denosumab

• ATRIO Study: Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporosis: A Phase IV, Low-Risk Int… Pending
  2025-522592-29-00 Phase IV 1 country Ospedale Galeazzi S.p.A.
• Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcom… Recruiting
  2024-518167-35-01 Phase II 1 country Associazione Italiana Ematologia Oncologia Pediatrica
• The effect of denosumab on muscle and strength and insulin sensitivity Recruiting
  2024-510637-18-00 Phase IV 1 country Region Midtjylland
• DEnosumab for the treatment of FIbrous Dysplasia/McCune-Albright Syndrome in adults (DeFiD): a randomized double-blind placebo-controlled tr… Recruiting
  2024-511090-30-00 Phase III/IV 1 country Leids Universitair Medisch Centrum (LUMC)
• The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind,… Recruiting
  2024-515365-34-00 Phase IV 1 country Region Hovedstaden
• Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or deno… Recruiting
  2024-513248-27-00 Phase III 1 country Institut De Cancerologie De L Ouest
• BRCA-P: A Cancer Prevention study to determine if Denosumab can prevent Breast Cancer Development in Women carrying a BRCA1 Germline Mutatio… Recruiting
  2024-513734-38-00 Phase III 3 countries Alliance Foundation Trials LLC; ANZ Breast Cancer Trials Group Limited; Institut…
• RGX Ended
  2024-514903-33-00 Phase II 1 country Region Midtjylland
• NT-NOA - Novel Treatment of some men with Non-Obstructive Azoospermia A clinical interventional trial Ended
  2024-512996-11-00 Phase II 1 country Region Hovedstaden
• NAPO - Novel Approach for Oligospermia Ended
  2023-508325-27-00 Phase II 1 country Herlev Hospital
• Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended
  2023-503790-37-00 Phase III 6 countries Curateq Biologics Private Limited
• Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis Ended
  2024-513591-18-00 Phase III 3 countries Shandong Boan Biotechnology Co. Ltd.
• Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid Ended
  2024-519705-36-00 Phase IV 4 countries NHS Lothian; University Of Edinburgh
• A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended
  2024-512417-41-00 Phase III 3 countries Xentria Inc.
• Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bone fractures caused by acute Cha… Ended
  2024-518637-28-00 Phase III 1 country Amsterdam UMC Stichting

Showing 1–15 of 15 trials